dipyridamole has been researched along with Glycogen Storage Disease Type I in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Glycogen Storage Disease Type I: An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycemia due to lack of glucose production. Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hemolysis is a frequent adverse effect of ribavirin (RBV)." | 9.11 | Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. ( Bihl, F; Grattagliano, I; Jüni, P; Lauterburg, BH; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S, 2004) |
| "Hemolysis is a frequent adverse effect of ribavirin (RBV)." | 5.11 | Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. ( Bihl, F; Grattagliano, I; Jüni, P; Lauterburg, BH; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grattagliano, I | 1 |
| Russmann, S | 1 |
| Palmieri, VO | 1 |
| Jüni, P | 1 |
| Bihl, F | 1 |
| Portincasa, P | 1 |
| Palasciano, G | 1 |
| Lauterburg, BH | 1 |
1 trial available for dipyridamole and Glycogen Storage Disease Type I
| Article | Year |
|---|---|
Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C.
Topics: Adult; Antiviral Agents; Cell Membrane; Dipyridamole; Erythrocytes; Female; Glutathione; Glutathione | 2004 |